Latest Content

Maurie Markman, MD, discusses the clinical utility of HPV vaccination as a strategy to prevent malignant disease.

Leah Wells, MD, breaks down the expansion and continued investigation of ADCs in lung cancer management.

Sintilimab plus adjuvant capecitabine did not improve 2-year PFS outcomes vs capecitabine alone in NPC with suboptimal response to induction chemotherapy.

Sharon Giordano will receive the Gianni Bonadonna Breast Cancer Award for significant contributions to breast cancer care and research .

First-line asandeutertinib improved intracranial iORR and IPFS vs osimertinib in EGFR-mutated NSCLC with brain metastases.

Selinexor plus ruxolitinib produced higher SVR35 rates than ruxolitinib alone in JAK inhibitor-naive myelofibrosis.

Zanidatamab plus tislelizumab and chemotherapy improved PFS and OS in HER2-positive mGEA regardless of PD-L1 status by TAP score or CPS.

TALAPRO-3 showed talazoparib plus enzalutamide cut progression or death risk by 52% in HRR-altered mCSPC vs enzalutamide alone.

A switch to camizestrant upon emergence of an ESR1 mutation improved PFS2 in ER-positive, HER2-negative advanced breast cancer.

PSMAddition subgroup data show lutetium PSMA-617 triplet yields consistent rPFS, PSA, and mCRPC benefits regardless of disease volume or mHSPC status.

OncLive spoke with urothelial cancer experts during Bladder Cancer Awareness Month to understand the current and future treatment landscape.

Sacituzumab govitecan plus pembrolizumab improved PFS2 and delayed subsequent therapy vs chemo/pembrolizumab in PD-L1+ mTNBC.

The FDA has approved orally disintegrating nilotinib tablets for select patients with chronic myeloid leukemia.